Exact Mass: 371.0796
Exact Mass Matches: 371.0796
Found 44 metabolites which its exact mass value is equals to given mass value 371.0796,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Arotinolol
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker[1]. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites[2]. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases[1].
Salicyluric beta-D-glucuronide
Salicyluric beta-D-glucuronide, also known as 1-O-salicyluroyl-beta-D-glucuronate or 1-O-[N-(2-hydroxybenzoyl)glycyl]-beta-D-glucronate, is a member of the class of compounds known as O-glucuronides. O-glucuronides are glucuronides in which the aglycone is linked to the carbohydrate unit through an O-glycosidic bond.
N,N-Bis(2-chloroethyl)-N',N'-diphenylphosphoric triamide
Arotinolol
N-(3-Cyano-1H-indol-5-yl)-3-[4-(trifluoromethoxy)phenyl]acrylamide
3-{3-[2-hydroxybut-3-en-1-yl]-1,2,4-thiadiazol-5-yl}-5,6-dihydrospiro[indoline-3,2-thiopyran]-2-one
2-N-BOC-3-(3-BROMO-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
2-N-BOC-3-(4-BROMO-PHENYL)-2-METHYLAMINOMETHYL-PROPIONIC ACID
1-{4-[3,5-DI(TRIFLUOROMETHYL)PHENOXY]PHENYL}-1H-PYRROLE
METHYL 2-N-BOC-2-AMINOMETHYL-3-(3-BROMO-PHENYL)-PROPIONATE
1H-1,3,4-Benzotriazepine,2-(2-thienyl)-5-[4-(trifluoromethyl)phenyl]-(9CI)
METHYL 2-N-BOC-2-AMINOMETHYL-3-(4-BROMO-PHENYL)-PROPIONATE
1-[(1,3,4-trimethyl-4,5-dihydroimidazol-1-ium-2-yl)oxy]pyrrolidine-2,5-dione,hexafluorophosphate
O-Succinimidyl-1,3-dimethylpropyleneuronium hexafluorophosphate
2-(3-Pyridinyl)-4-[4-(1-pyrrolidinylsulfonyl)phenyl]thiazole
N-[6-acetyl-3-(1,3-benzothiazol-2-yl)-5,7-dihydro-4H-thieno[2,3-c]pyridin-2-yl]acetamide
2-(Cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate
4-[5-Amino-3-methyl-4-[oxo-[3-(trifluoromethyl)phenyl]methyl]-2-thiophenyl]butanoic acid
3-(1,3-benzothiazol-2-ylsulfanyl)-N-[(E)-(4-methoxyphenyl)methylideneamino]propanamide
ethyl 4-{(4E)-4-[(5-nitrofuran-2-yl)methylidene]-3,5-dioxopyrazolidin-1-yl}benzoate
(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
AS1949490
AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC50 values of 0.34, 0.62, 13, >50, >50, and >50 μM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes[1][2].
Azemiglitazone
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury[4][5].
Quinotolast sodium
Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner.
